Market LIVE
Published markets; coverage varies by country
Product profile · United States

Avastin

 ·  Patent Litigation & Settlement History ↓

Ingredientbevacizumab
Application typeBLA
Application125085
Product002
Dosage formInjection
RouteIntravenous
Strength400MG/16ML (25MG/ML)
Approval date2004-02-26
Marketing statusRx
Status event—
ApplicantGenentech, Inc.
Product source

Current GenericRadar decision

Year2016
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeEXCLUSIVITY
Anchor date2016-02-26
Patent anchor—
Exclusivity anchor2016-02-26
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2016. Anchor type: EXCLUSIVITY. Patent anchor: not recorded. Exclusivity anchor: 2016-02-26. Anchor date: 2016-02-26. Patent tail: not established. Exclusivity tail: not established. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
97956722024-05-28PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
74857042025-03-08PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
109069862028-07-08PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
110782942028-07-08PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
85748692028-07-08PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
84608952029-08-08PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
109820032030-08-06PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
97142932030-08-06PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
85129832031-01-04PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
100118562031-05-26PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
106622372031-08-07PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
107040712031-08-18PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
94878092032-01-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
105136972032-09-17PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
109069342033-10-12PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
100177322034-03-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
106767102034-03-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
108297322034-03-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
94410352034-04-23PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
102744662035-07-11PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
102083552035-07-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
103369832035-07-31PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
Orphan Exclusivity Exp. Date—2027-05-29————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
761028 / 001BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2017-09-14—Amgen Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761028 / 002BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2017-09-14—Amgen Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761099 / 001BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2019-06-27—Pfizer Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761099 / 002BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2019-06-27—Pfizer Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761231 / 001BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2022-04-13—Amneal Pharmaceuticals LLCNREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761231 / 002BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2022-04-13—Amneal Pharmaceuticals LLCNREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761268 / 001BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2022-09-27—CELLTRION, Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761268 / 002BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2022-09-27—CELLTRION, Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761198 / 001BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2023-12-06—Bio-Thera Solutions, Ltd.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761198 / 002BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2023-12-06—Bio-Thera Solutions, Ltd.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761175 / 001BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2025-04-09—Biocon Biologics Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761175 / 002BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2025-04-09—Biocon Biologics Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 12 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
761028 / 001Amgen Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2017-09-14 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761028 / 002Amgen Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2017-09-14 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761099 / 001Pfizer Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2019-06-27 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761099 / 002Pfizer Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2019-06-27 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761231 / 001Amneal Pharmaceuticals LLCBIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2022-04-13 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761231 / 002Amneal Pharmaceuticals LLCBIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2022-04-13 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761268 / 001CELLTRION, Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2022-09-27 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761268 / 002CELLTRION, Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2022-09-27 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761198 / 001Bio-Thera Solutions, Ltd.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2023-12-06 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761198 / 002Bio-Thera Solutions, Ltd.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2023-12-06 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761175 / 001Biocon Biologics Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2025-04-09 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761175 / 002Biocon Biologics Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2025-04-09 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
BLA_PATENT_EXCLUSIVITY_REVIEW—BUSINESS_CLASSIFICATION_WITH_CONDITIONSEnglish description not available.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.